Synergy CHC Amends Term Loan with Onerous Conditions, Mandates $10M Equity Raise, and Issues Dilutive Warrants

summarizeSummary

Synergy CHC Corp. amended its term loan, imposing a mandatory $10M equity raise by September 2026 with a penalty for non-compliance, issued highly dilutive warrants to a lender, and revealed severe leverage, signaling significant financial distress.

check_boxKey Events

• Term Loan Agreement Amended

  The company entered into a second amendment to its term loan credit agreement, originally dated May 30, 2025, revising amortization schedules, interest payment mechanics, pricing, and financial covenants.

• Mandatory $10M Equity Raise Condition

  A critical condition requires the company to raise at least $10,000,000 in net cash proceeds from equity issuances by September 30, 2026. Failure to meet this target will result in a 2.00% per annum increase in the Applicable Margin on the loan.

• Highly Dilutive Warrant Issued to Lender

  Synergy CHC Corp. issued a common stock purchase warrant to Acme Credit Partners Fund I, LP, allowing the holder to purchase 3,000,000 shares of common stock at an exercise price of $0.00001 per share, exercisable upon a Qualified Event of Default.

• Interest Paid In Kind (PIK) and High Leverage

  Interest due on March 2, 2026, was paid in kind by capitalizing it to the principal, with an option for April 1, 2026, interest to also be paid in kind. The company reported an extremely high Consolidated Senior Net Leverage Ratio of 20.00:1.00 for the fiscal quarter ended December 31, 2025.

auto_awesomeAnalysis

Synergy CHC Corp. has amended its existing term loan credit agreement, confirming prior news and revealing significant financial distress and stringent new conditions. The amendment introduces a mandatory requirement to raise at least $10,000,000 in net cash proceeds from equity issuances by September 30, 2026, with a severe penalty of a 2.00% per annum interest rate step-up if this condition is not met. This is a substantial amount relative to the company's market capitalization, indicating an urgent need for capital and potential for significant shareholder dilution. The company also issued a warrant to a lender to purchase 3,000,000 shares of common stock at a nominal exercise price of $0.00001 per share, exercisable upon an event of default, further highlighting the concessions made to secure the amended loan. The ability to pay interest in kind for March and potentially April 2026, along with an extremely high consolidated senior net leverage ratio of 20.00:1.00 for Q4 2025, underscores the company's precarious financial position. Investors should monitor the company's progress on the equity raise and the impact of potential dilution.